These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30844849)

  • 1. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
    Den RB; George D; Pieczonka C; McNamara M
    Am J Clin Oncol; 2019 Apr; 42(4):399-406. PubMed ID: 30844849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
    Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
    Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
    Miranda J; Viñal D; Pinto Á
    Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current approaches to incorporation of radium-223 in clinical practice.
    Parker C; Heidenreich A; Nilsson S; Shore N
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Palliative
    Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
    J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
    König F; Strauß A; Johannsen M; Mommsen C; Fricke E; Klier J; Mehl S; Pfister D; Sahlmann CO; Werner A; Goebell PJ
    Urologe A; 2020 Jan; 59(1):53-64. PubMed ID: 31598745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radium-223 as an Approved Modality for Treatment of Bone Metastases.
    Brito AE; Etchebehere E
    Semin Nucl Med; 2020 Mar; 50(2):177-192. PubMed ID: 32172803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
    Jacene H; Gomella L; Yu EY; Rohren EM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
    Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Sartor O; Appukkuttan S; Weiss J; Tsao CK
    Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
    Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
    Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
    Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
    Buroni FE; Persico MG; Pasi F; Lodola L; Nano R; Aprile C
    Anticancer Res; 2016 Nov; 36(11):5719-5730. PubMed ID: 27793893
    [No Abstract]   [Full Text] [Related]  

  • 19. Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.
    Unda-Urzaiz M; Sousa-Campo R; Rodríguez-Antolín A; Silva-Marins C; Juárez-Soto A; Miñana-López B; Figueiredo-de Castro A; Cozar-Olmos JM
    Actas Urol Esp (Engl Ed); 2018 May; 42(4):227-237. PubMed ID: 28711312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.